Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 5/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694067 | 0.93 | JAK3 (0.44) | KMT2ABTKJAK3JAK2 | |
| SCHEMBL1783130 | 0.93 | KMT2A (0.43) | KMT2APAK1BTK | |
| SCHEMBL28333053 | 0.85 | KMT2A (0.56) | KMT2ACCNKCDK12BTK | |
| SCHEMBL3434611 | 0.85 | KMT2A (0.56) | KMT2ACCNKCDK12BTK | |
| SCHEMBL2334905 | 0.85 | ABL1 (0.41) | KMT2ACCNKCDK12PAK1BTK | |
| SCHEMBL18001112 | 0.83 | BTK (0.49) | BTKPIK3CD | |
| SCHEMBL19665697 | 0.82 | MAPK8 (0.45) | CCNKCDK12BTKJAK3 | |
| SCHEMBL2331318 | 0.81 | AXL (0.44) | BTKJAK3JAK2 | |
| SCHEMBL19665640 | 0.81 | HSD11B1 (0.47) | KMT2ACCNKCDK12JAK3JAK2 | |
| SCHEMBL19665596 | 0.81 | MAPK8 (0.46) | CCNKCDK12BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2131844-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV Therapeutics Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008123891-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | LIGAND PHARMACEUTICALS INCORPORATED | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | KMT2A 1488/4885CCNK 1525/4885CDK12 1806/4885 |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | KMT2A 1488/4885CCNK 1525/4885CDK12 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.